Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Syno Capital is a global investment firm founded in 2015 and headquartered in New York, with additional offices in Hong Kong and Shanghai. The firm specializes in life sciences and healthcare investing, focusing on breakthrough innovations that address pressing healthcare challenges. Since its inception, Syno Capital has positioned itself as a key player in the healthcare investment space, emphasizing scientific research and data-driven decision-making.
The firm operates with a commitment to supporting companies that are poised to make a significant impact in the healthcare sector. Syno Capital's unique value proposition lies in its ability to facilitate the expansion of US portfolio companies into the Greater China region, leveraging its cross-border expertise and extensive network. This strategic focus allows Syno Capital to bridge the gap between two of the world's largest healthcare markets.
Syno Capital invests primarily in healthcare innovations, employing a disciplined investment approach guided by scientific research. The firm targets sectors such as therapeutics, medical devices, and digital health, aiming to tackle significant challenges within the healthcare industry. Their investment strategy is characterized by a rigorous analysis of potential investments, ensuring that they align with the firm’s mission to address pressing healthcare issues.
In addition to its focus on innovation, Syno Capital emphasizes the importance of collaboration with leading minds in the healthcare sector. The firm seeks to partner with companies that demonstrate the potential for transformative impact in healthcare delivery and outcomes. Syno Capital's investment philosophy is built on three pillars: innovation, rigor, and discipline, which guide their decision-making process.
Syno Capital's portfolio includes six companies, with a notable investment in ORIG3N, a biotech firm that develops treatments for rare and genetically inherited diseases. ORIG3N operates the world's largest induced pluripotent stem cell (iPSC) bank, showcasing the firm's commitment to supporting groundbreaking healthcare innovations. This investment highlights Syno Capital's focus on companies that are at the forefront of scientific advancement in the healthcare sector.
While the firm has a small portfolio, its selective investment strategy indicates a focus on quality over quantity. The sectors represented in their portfolio include biotech, healthcare, digital health, and medical devices, aligning with their overarching investment thesis of addressing significant healthcare challenges.
To pitch to Syno Capital, founders should visit their website at synocapital.com. The pitch deck should include comprehensive information about the startup's technology, market potential, and team qualifications. While specific response time expectations are not disclosed, it is advisable to follow up after a reasonable period if no communication is received.
Warm introductions are preferred, as they can enhance the likelihood of a favorable review. Founders should ensure that their pitch clearly aligns with Syno Capital's focus on healthcare innovations and their investment thesis.
What are Syno Capital's investment criteria?
Syno Capital focuses on healthcare innovations, particularly in therapeutics, medical devices, and digital health. The firm seeks companies that demonstrate the potential to address significant healthcare challenges through scientific research and innovation.
How can founders pitch to Syno Capital?
Founders can submit their pitches through the firm's website at synocapital.com. It is recommended to include detailed information about the company's technology, market potential, and team background in the pitch deck.
What makes Syno Capital different from other venture capital firms?
Syno Capital differentiates itself through its cross-border expertise, particularly in bridging US and Greater China healthcare markets. This unique positioning allows the firm to provide valuable support to US portfolio companies looking to expand into Asia.
What is the typical check size for investments?
While specific check sizes are not publicly disclosed, Syno Capital invests across seed, early, and later stages, indicating a flexible approach to funding based on the needs of the portfolio companies.
What is Syno Capital's post-investment involvement like?
The firm emphasizes collaboration and support for its portfolio companies, particularly in navigating the complexities of entering the Greater China market. This includes leveraging their network and expertise to facilitate growth and expansion.
What is the size of Syno Capital's fund?
The fund size has not been publicly disclosed, but the firm maintains a selective investment strategy, which suggests a focus on high-impact opportunities rather than a large volume of investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.